Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the captioned application:

Listing of Claims:

Claim 1 (previously presented): A composition for forming a compressed solid dosage form comprising a free-flowing compressible admixture of simethicone and an adsorbent, wherein the weight ratio of simethicone to adsorbent is at least about 1:2.22, wherein the absorbent comprises a combination of magnesium aluminometasilicate and silicified microcrystalline cellulose.

Claim 2 (previously presented): A composition of claim 1, wherein the weight ratio of simethicone to adsorbent is at least about 1:2.00.

Claim 3 (cancelled)

Claim 4 (original): A composition of claim 1, further comprising at least one additional active agent.

Claim 5 (previously presented): A composition of claim 4, wherein the active agent is selected from the group consisting of bisacodyl, famotidine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.

Claim 6 (withdrawn): A composition of claim 5, wherein the active agent is loperamide, or pharmaceutically acceptable salts, esters, or isomers thereof.

Claim 7 (original): A composition of claim 1 having at least 34% simethicone.

Claim 8 (original): A composition of claim 7, having from about 35wt% to about 54wt% simethicone.

Claim 9 (previously presented): A composition of claim 3 having from about 19 wt% to about 27 wt% silicified microcrystalline cellulose and having from about 31 wt% to about 39 wt% magnesium aluminometasilicate.

Claim 10 (original): A composition of claim 9 having from about 23 wt% to about 27 wt% silicified microcrystalline cellulose and from about 33wt% to about 37 wt% magnesium aluminometasilicate.

Claim 11 (original): A composition of claim 1, wherein the composition is compressed into a tablet having a hardness value of at least 2 kp/cm^2.

Claim 12 (original): A composition of claim 11, wherein the composition is compressed into a tablet having a hardness value of from about 5 to about 10 kp/cm^2.

Claim 13 (original): A solid oral dosage form comprising a compressed admixture of simethicone, silicified microcrystalline cellulose, and magnesium aluminometasilicate, wherein the simethicone is adsorbed on the silicified microcrystalline cellulose and magnesium aluminometasilicate.

Claim 14 (previously presented): A solid oral dosage form of claim 13, wherein the weight ratio of simethicone to silicified microcrystalline cellulose and magnesium aluminometasilicate is at least about 1:2.00.

Claim 15 (cancelled).

Claim 16 (original): A solid oral dosage form of claim 13, further comprising at least one additional active agent.

Claim 17 (previously presented): A solid oral dosage form of claim 16, wherein the active agent is selected from the group consisting of bisacodyl, famotidine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.

Claim 18 (withdrawn): A solid oral dosage form of claim 17, wherein the active agent is loperamide, or pharmaceutically acceptable salts, esters, or isomers thereof.

Claim 19 (original): A solid oral dosage form of claim 13 having at least 30 wt% simethicone.

Claim 20 (original): A solid oral dosage form of claim 19, having from about 31 wt% to about 35 wt% simethicone.

Claim 21 (original): A solid oral dosage form of claim 13 having from about 19 wt% to about 27 wt% silicified microcrystalline cellulose and having from about 31 wt% to about 39 wt% magnesium aluminometasilicate.

Claim 22 (original): A solid oral dosage form of claim 21 having from about 23 wt% to about 27 wt% silicified microcrystalline cellulose and from about 33wt% to about 37 wt% magnesium aluminometasilicate.

Claim 23 (previously presented): A solid oral dosage form of claim 13, wherein the compressed admixture is a tablet having a hardness value of at least 2 kp/cm^2.

Claim 24 (previously presented): A solid oral dosage form of claim 13, wherein the compressed admixture is a tablet having a hardness value of from about 5 to about 10 kp/cm^2.

Claim 25 (original): A composition for forming a solid dosage form comprising a free-flowing compressible admixture of simethicone, silicified microcrystalline cellulose, magnesium aluminometasilicate.

Claim 26 (previously presented): A compressed solid dosage form comprising an admixture of simethicone, silicified microcrystalline cellulose, magnesium aluminometasilicate, wherein the weight ratio of simethicone to silicified microcrystalline cellulose and magnesium aluminometasilicate is at least 1:2.00.

Claim 27 (withdrawn): A composition of claim 5, wherein the active agent is bisacodyl, or pharmaceutically acceptable salts, esters, or isomers thereof.

Claim 28 (withdrawn): A composition of claim 4, wherein the active agent is selected from the group consisting of acetaminophen, ibuprofen, naproxen, ketoprofen, cyclobenzaprine, meloxicam, rofecoxib, celecoxib, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.

Claim 29 (new): A solid dosage unit simethicone and an adsorbent comprising magnesium aluminometasilicate and silicified microcrystalline cellulose, wherein the proportionate amounts, by weight, is about 1: about 0.5 to about 0.85 : about 0.9 to about 1.30 per solid dosage unit.